Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.
Publication
, Journal Article
Alfredsson, J; Roe, MT
Published in: J Am Heart Assoc
March 19, 2015
Duke Scholars
Published In
J Am Heart Assoc
DOI
EISSN
2047-9980
Publication Date
March 19, 2015
Volume
4
Issue
3
Start / End Page
e001897
Location
England
Related Subject Headings
- Secondary Prevention
- Receptor, PAR-1
- Pyridines
- Platelet Aggregation Inhibitors
- Peripheral Arterial Disease
- Myocardial Infarction
- Male
- Lactones
- Humans
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Alfredsson, J., & Roe, M. T. (2015). Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc, 4(3), e001897. https://doi.org/10.1161/JAHA.115.001897
Alfredsson, Joakim, and Matthew T. Roe. “Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.” J Am Heart Assoc 4, no. 3 (March 19, 2015): e001897. https://doi.org/10.1161/JAHA.115.001897.
Alfredsson J, Roe MT. Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc. 2015 Mar 19;4(3):e001897.
Alfredsson, Joakim, and Matthew T. Roe. “Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.” J Am Heart Assoc, vol. 4, no. 3, Mar. 2015, p. e001897. Pubmed, doi:10.1161/JAHA.115.001897.
Alfredsson J, Roe MT. Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc. 2015 Mar 19;4(3):e001897.
Published In
J Am Heart Assoc
DOI
EISSN
2047-9980
Publication Date
March 19, 2015
Volume
4
Issue
3
Start / End Page
e001897
Location
England
Related Subject Headings
- Secondary Prevention
- Receptor, PAR-1
- Pyridines
- Platelet Aggregation Inhibitors
- Peripheral Arterial Disease
- Myocardial Infarction
- Male
- Lactones
- Humans
- Female